Evidence map›Paper›PMID 31398819›Full record

ReviewInternational journal of molecular sciences2019

Prospective Application of Activity-Based Proteomic Profiling in Vision Research-Potential Unique Insights into Ocular Protease Biology and Pathology.

Hui Peng, John D Hulleman

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Hui PengDepartment of Ophthalmology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9057, USA.
John D HullemanDepartment of Ophthalmology, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9057, USA. John.Hulleman@UTSouthwestern.edu.

Funding

Core Grant for Vision ResearchP30EY020799 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI NIEDERKORN, JERRY · 2010 to 2016
$4.1M
Supplement to Promote Diversity in Health-Related Research - Prevention of macular pathophysiology...Parent GrantR01EY027785 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI John Douglas Hulleman · 2018 to 2026
$2.8M
A broadly applicable, regulatable strategy to control signaling in the retina.R21EY028261 · NEI · UT SOUTHWESTERN MEDICAL CENTER · PI HULLEMAN, JOHN DOUGLAS · 2017 to 2018
$446k
BrightFocus Foundation M2018099NEI NIH HHS P30 EY020799NEI NIH HHS R01 EY027785NEI NIH HHS R21 EY028261NIH HHS EY020799NIH HHS EY027785NIH HHS EY028261Research to Prevent Blindness Career Development AwardResearch to Prevent Blindness Unrestricted Grant
6 · The paper itself

Abstract

Activity-based proteomic profiling (ABPP) is a powerful tool to specifically target and measure the activity of a family of enzymes with the same function and reactivity, which provides a significant advantage over conventional proteomic strategies that simply provide abundance information. A number of inherited and age-related eye diseases are caused by polymorphisms/mutations or abnormal expression of proteases including serine proteases, cysteine proteases, and matrix metalloproteinases, amongst others. However, neither conventional genomic, transcriptomic, nor traditional proteomic profiling directly interrogate protease activities. Thus, leveraging ABPP to probe the activity of these enzyme classes as they relate to normal function and pathophysiology of the eye represents a unique potential opportunity for disease interrogation and possibly intervention.

Indexed as

ProteomeProteomicsAnimalsDisease SusceptibilityEyeEye DiseasesEye ProteinsHumansPeptide HydrolasesResearchResearch DesignEye ProteinsPeptide HydrolasesProteomeage-related macular degenerationchemical biologyenzyme activityeye diseaseproteasesretinal degeneration

Identifiers

PMID31398819
PMCPMC6720450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.